REPL: Replimune Group, Inc.
Performance
REPL +167.87%
Watchlist
Select an item
Summary
REPL at a glance
REPL returned +167.87% over the past year and -7.80% a year over five years. Its worst drop in that year was -84.16%, smaller than 1% of stocks on Redstone, and its Sharpe ratio of 1.36 beats 88% of stocks on Redstone. It pays no dividends.
Current Drawdown
0.00%
Rolling Volatility
109.25%
Actions
Metrics
Risk Indicators
Alpha236.63%
Beta1.91x
Sharpe1.36
Sortino2.69
Omega1.45
Calmar1.99
Martin8.14
Profile
About REPL
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $2.1B
- Listed
- Jul 2018
- Employees
- 465
- Headquarters
- Woburn, MA
- Website
- replimune.com
Comparisons